Zai Lab Plans to Seek Efgartigimod Approval in China in Early 2022

Zai Lab Plans to Seek Efgartigimod Approval in China in Early 2022

311728

Zai Lab Plans to Seek Efgartigimod Approval in China in Early 2022

Zai Lab is planning — in the first half of 2022 — to ask Chinese authorities to approve efgartigimod (ARGX-113) as a treatment for generalized myasthenia gravis (gMG) in that country. The therapy, being developed by Argenx and designed to lessen the body’s immune attacks against its own healthy tissues, currently is under review in the U.S., the EU, and Japan. Earlier this year, Argenx and Zai Lab struck a deal under which Zai will be…

You must be logged in to read/download the full post.